NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. için elimizdeki en son çeyrek

Şirketin kendi 6-K belgesinden.

Yönetim ne dedi

“Our focus remains on advancing PrimeC toward the next stage of development and, ultimately, toward patients,”

Açıklamadan birebir alıntılanmıştır ve yalnızca belge sözü adı geçen bir kişiye atfettiğinde gösterilir.

NeuroSense Therapeutics Ltd. ne yapar

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within approximately 3 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Şirketin kendi tanımı, açıklamanın sonunda göründüğü hâliyle.